KMT2A and leukemia: Similarly, a transgenic mouse model simultaneously expressing MLL-AF4 and an activated KRAS mutated gene showed a shortened leukaemia latency11, which prompted for renewed KRAS and NRAS mutation screenings in MLL rearranged and wild type infant and paediatric patients.